vs
Idexx Laboratories（IDXX）与捷迈邦美（ZBH）财务数据对比。点击上方公司名可切换其他公司
捷迈邦美的季度营收约是Idexx Laboratories的1.9倍（$2.1B vs $1.1B），Idexx Laboratories净利率更高（22.8% vs 11.4%，领先11.3%），Idexx Laboratories同比增速更快（14.3% vs 9.3%），Idexx Laboratories自由现金流更多（$326.3M vs $245.9M），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs 3.7%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
捷迈邦美是一家美国上市的医疗设备企业，1927年成立，最初以生产铝制夹板为核心业务，总部设于印第安纳州华沙市，是当地医疗设备产业集群的核心成员，在全球骨科医疗器械领域拥有较高知名度。
IDXX vs ZBH — 直观对比
营收规模更大
ZBH
是对方的1.9倍
$1.1B
营收增速更快
IDXX
高出5.0%
9.3%
净利率更高
IDXX
高出11.3%
11.4%
自由现金流更多
IDXX
多$80.4M
$245.9M
两年增速更快
IDXX
近两年复合增速
3.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.1B |
| 净利润 | $248.2M | $238.3M |
| 毛利率 | 60.3% | 64.6% |
| 营业利润率 | 28.9% | 17.9% |
| 净利率 | 22.8% | 11.4% |
| 营收同比 | 14.3% | 9.3% |
| 净利润同比 | 14.8% | 30.5% |
| 每股收益（稀释后） | $3.09 | $1.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXZBH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $1.1B | $2.1B | ||
| Q1 25 | $998.4M | $1.9B | ||
| Q4 24 | $954.3M | $2.0B | ||
| Q3 24 | $975.5M | $1.8B | ||
| Q2 24 | $1.0B | $1.9B |
净利润IDXXZBH
| Q1 26 | — | $238.3M | ||
| Q4 25 | $248.2M | $139.4M | ||
| Q3 25 | $274.6M | $230.9M | ||
| Q2 25 | $294.0M | $152.8M | ||
| Q1 25 | $242.7M | $182.0M | ||
| Q4 24 | $216.1M | $239.5M | ||
| Q3 24 | $232.8M | $249.1M | ||
| Q2 24 | $203.3M | $242.8M |
毛利率IDXXZBH
| Q1 26 | — | 64.6% | ||
| Q4 25 | 60.3% | 64.7% | ||
| Q3 25 | 61.8% | 72.1% | ||
| Q2 25 | 62.6% | 71.5% | ||
| Q1 25 | 62.4% | 71.2% | ||
| Q4 24 | 59.8% | 71.0% | ||
| Q3 24 | 61.1% | 70.5% | ||
| Q2 24 | 61.7% | 71.5% |
营业利润率IDXXZBH
| Q1 26 | — | 17.9% | ||
| Q4 25 | 28.9% | 6.9% | ||
| Q3 25 | 32.1% | 17.6% | ||
| Q2 25 | 33.6% | 14.4% | ||
| Q1 25 | 31.7% | 15.3% | ||
| Q4 24 | 27.4% | 19.2% | ||
| Q3 24 | 31.2% | 15.3% | ||
| Q2 24 | 26.3% | 18.1% |
净利率IDXXZBH
| Q1 26 | — | 11.4% | ||
| Q4 25 | 22.8% | 6.2% | ||
| Q3 25 | 24.8% | 11.5% | ||
| Q2 25 | 26.5% | 7.4% | ||
| Q1 25 | 24.3% | 9.5% | ||
| Q4 24 | 22.7% | 11.8% | ||
| Q3 24 | 23.9% | 13.7% | ||
| Q2 24 | 20.3% | 12.5% |
每股收益（稀释后）IDXXZBH
| Q1 26 | — | $1.22 | ||
| Q4 25 | $3.09 | $0.71 | ||
| Q3 25 | $3.40 | $1.16 | ||
| Q2 25 | $3.63 | $0.77 | ||
| Q1 25 | $2.96 | $0.91 | ||
| Q4 24 | $2.62 | $1.18 | ||
| Q3 24 | $2.80 | $1.23 | ||
| Q2 24 | $2.44 | $1.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $424.2M |
| 总债务越低越好 | $450.0M | $7.5B |
| 股东权益账面价值 | $1.6B | $12.7B |
| 总资产 | $3.4B | $22.7B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资IDXXZBH
| Q1 26 | — | $424.2M | ||
| Q4 25 | $180.1M | $591.9M | ||
| Q3 25 | $208.2M | $1.3B | ||
| Q2 25 | $164.6M | $556.9M | ||
| Q1 25 | $164.0M | $1.4B | ||
| Q4 24 | $288.3M | $525.5M | ||
| Q3 24 | $308.6M | $569.0M | ||
| Q2 24 | $401.6M | $420.1M |
总债务IDXXZBH
| Q1 26 | — | $7.5B | ||
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益IDXXZBH
| Q1 26 | — | $12.7B | ||
| Q4 25 | $1.6B | $12.7B | ||
| Q3 25 | $1.6B | $12.8B | ||
| Q2 25 | $1.5B | $12.5B | ||
| Q1 25 | $1.4B | $12.4B | ||
| Q4 24 | $1.6B | $12.5B | ||
| Q3 24 | $1.6B | $12.4B | ||
| Q2 24 | $1.6B | $12.7B |
总资产IDXXZBH
| Q1 26 | — | $22.7B | ||
| Q4 25 | $3.4B | $23.1B | ||
| Q3 25 | $3.4B | $23.5B | ||
| Q2 25 | $3.3B | $22.9B | ||
| Q1 25 | $3.2B | $22.2B | ||
| Q4 24 | $3.3B | $21.4B | ||
| Q3 24 | $3.4B | $21.7B | ||
| Q2 24 | $3.4B | $21.5B |
负债/权益比IDXXZBH
| Q1 26 | — | 0.59× | ||
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $359.4M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $245.9M |
| 自由现金流率自由现金流/营收 | 29.9% | 11.8% |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 1.43× | 1.51× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $1.4B |
8季度趋势，按日历期对齐
经营现金流IDXXZBH
| Q1 26 | — | $359.4M | ||
| Q4 25 | $355.8M | $517.4M | ||
| Q3 25 | $402.3M | $418.7M | ||
| Q2 25 | $185.7M | $378.2M | ||
| Q1 25 | $238.0M | $382.8M | ||
| Q4 24 | $262.0M | $506.3M | ||
| Q3 24 | $220.1M | $395.7M | ||
| Q2 24 | $248.3M | $369.4M |
自由现金流IDXXZBH
| Q1 26 | — | $245.9M | ||
| Q4 25 | $326.3M | $442.6M | ||
| Q3 25 | $371.2M | $363.7M | ||
| Q2 25 | $151.6M | $328.1M | ||
| Q1 25 | $207.9M | $338.2M | ||
| Q4 24 | $232.8M | $454.8M | ||
| Q3 24 | $192.0M | $351.2M | ||
| Q2 24 | $215.0M | $316.7M |
自由现金流率IDXXZBH
| Q1 26 | — | 11.8% | ||
| Q4 25 | 29.9% | 19.7% | ||
| Q3 25 | 33.6% | 18.2% | ||
| Q2 25 | 13.7% | 15.8% | ||
| Q1 25 | 20.8% | 17.7% | ||
| Q4 24 | 24.4% | 22.5% | ||
| Q3 24 | 19.7% | 19.3% | ||
| Q2 24 | 21.4% | 16.3% |
资本支出强度IDXXZBH
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 3.3% | ||
| Q3 25 | 2.8% | 2.7% | ||
| Q2 25 | 3.1% | 2.4% | ||
| Q1 25 | 3.0% | 2.3% | ||
| Q4 24 | 3.1% | 2.5% | ||
| Q3 24 | 2.9% | 2.4% | ||
| Q2 24 | 3.3% | 2.7% |
现金转化率IDXXZBH
| Q1 26 | — | 1.51× | ||
| Q4 25 | 1.43× | 3.71× | ||
| Q3 25 | 1.47× | 1.81× | ||
| Q2 25 | 0.63× | 2.48× | ||
| Q1 25 | 0.98× | 2.10× | ||
| Q4 24 | 1.21× | 2.11× | ||
| Q3 24 | 0.95× | 1.59× | ||
| Q2 24 | 1.22× | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
ZBH
暂无分部数据
